Evidence for different effects of soluble TNF-receptors on various TNF measurements in human biological fluids

The Lancet

Volumn 338, Issue 8765, 1991, Pages 515-516

  Engelberts, I ^a,b   Stephens, S ^a,b   Francot, G J M ^a,b   Van Der Linden, C J ^a,b   Buurman, W A ^a,b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b UCB PHARMA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

BODY FLUID; CANCER; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; IMMUNOASSAY; LETTER; PRIORITY JOURNAL;

BIOLOGICAL ASSAY; BODY FLUIDS; HUMAN; NEOPLASMS; RECEPTORS, CELL SURFACE; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR;

EID: 0025740571     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/0140-6736(91)90591-C     Document Type: Letter

References (11)

1. Evidence for tumour necrosis factor/cachectin production in cancer
2. Tumour-necrosis factor in normal plasma
3. Induction of circulating tumour necrosis factor (TNFα) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients
4. Endogenous tumour necrosis factor in cancer patients
5. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease
6. Plasma tumor necrosis factor levels in patients with presumed sepsis results in those treated with antilipid A antibody vs placebo
7. Tumor necrosis factor and interleukin-1 m the serum of children with severe infectious purpura
8. Serum tumor necrosis factor levels in patients with infectious disease and septic shock
9. Evaluation of measurement of human TNF in plasma by ELISA
10. Shedding of tumor necrosis factor receptors by activated human neutrophils
11. Induction of plasma inhibitors of interleukin 1 and TNF-α activity by endotoxin administration to normal humans